Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatoce
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatoce is one of 9,000 studies in the ScholarPulse dataset. Key details — Authors: Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang‐Hyub Han, Kenji Ikeda, Fabio Piscaglia; Journal / source: The Lancet; Year: 2018.
| Authors | Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang‐Hyub Han, Kenji Ikeda, Fabio Piscaglia |
|---|---|
| Journal / source | The Lancet |
| Year | 2018 |
| Field | Hepatocellular Carcinoma Treatment and Prognosis |
| Times cited | 5430 |
| Type | article |
| DOI / link | https://doi.org/10.1016/s0140-6736(18)30207-1 |